Cibus (CBUS) Raw Materials (2019 - 2020)
Cibus (CBUS) posted Raw Materials of $1.4 million for Q4 2020, down 66.24% sequentially from $4.1 million in Q3 2020, and down 37.45% YoY from $2.2 million in Q1 2020.
Cibus (CBUS) Raw Materials (2019 - 2020) Analysis & Trends
Cibus has reported Raw Materials for 2 years, with the latest figure at $1.4 million in Q4 2020.
- Quarterly Raw Materials fell 37.45% year-over-year to $1.4 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $1.4 million (down 37.45% YoY) and the FY2020 annual result came in at $1.4 million, down 37.45% from the prior year.
- Raw Materials fell to $1.4 million in Q4 2020 per CBUS's latest filing, from $4.1 million in the prior quarter.
- Over five years, Raw Materials peaked at $4.3 million in Q2 2020 and troughed at $79000.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Cibus | 132.02 Mn | 111.59 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 1.38 Mn |
| Sep 30, 2020 | 4.10 Mn |
| Jun 30, 2020 | 4.33 Mn |
| Mar 31, 2020 | 2.54 Mn |
| Dec 31, 2019 | 2.21 Mn |
| Sep 30, 2019 | 1.99 Mn |
| Jun 30, 2019 | 79,000.00 |